<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6373">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01677403</url>
  </required_header>
  <id_info>
    <org_study_id>qlhqiqian</org_study_id>
    <secondary_id>QL</secondary_id>
    <nct_id>NCT01677403</nct_id>
  </id_info>
  <brief_title>A Study to Access Safety and Efficacy of Nebulized Tobramycin in Patients With Bronchiectasis</brief_title>
  <official_title>A Randomized,Controlled Study to Evaluate the Efficacy,Indications,Adverse Reactions and Resistance of Combined Administration of Nebulized Tobramycin Compared With Systemic Administration Alone in Patients With Bronchiectasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong University</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate the efficacy,indications,adverse reactions and resistance of
      combined administration of nebulized tobramycin compared with systemic administration alone
      in patients with Bronchiectasis in acute exacerbation of Bronchiectasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bronchiectasis is a chronic disorder of the major bronchi and bronchioles characterized by
      permanent dilation, microbial infection, a persistent inflammatory response with the release
      of immune mediators and microbial toxins leading to destruction. The origin of
      bronchiectasis varies, but the presence of microbial infection and a persistent inflammatory
      response is typical of the disease. The chronic nature of the infection and the associated
      considerable morbidity provides the rationale for using aerosolized antibiotics for the
      treatment of bronchiectasis patients.

      This is a study of safety and efficacy of combined administration of nebulized tobramycin
      compared with systemic administration alone in patients with Bronchiectasis in acute
      exacerbation of Bronchiectasis. Study subjects will be randomized to receive either study
      drug or placebo by inhalation via a nebulizer. Each subject will complete 14 days of daily
      dosing.

      Clinical laboratory parameters,clinical adverse events and pulmonary function will be
      evaluated for all study subjects in order to determine the qualitative and quantitative
      safety and efficacy of nebulized tobramycin.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>To evaluate change in density of Pseudomonas aeruginosa in sputum</measure>
    <time_frame>days 1,7,14</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate chang in the amount of sputum</measure>
    <time_frame>days 1,7,14</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate chang in patients' cough severity</measure>
    <time_frame>days 1,7,14</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate change in pulmonary function</measure>
    <time_frame>days 1,7,14</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Bronchiectasis</condition>
  <arm_group>
    <arm_group_label>Nebulised Tobramycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nebulised Tobramycin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nebulised 0.9% Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Nebulised 0.9% Saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tobramycin</intervention_name>
    <description>Nebulised 80mg twice daily</description>
    <arm_group_label>Nebulised Tobramycin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Nebulised 5mls 0.9% Saline twice daily</description>
    <arm_group_label>Nebulised 0.9% Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female study subjects ≥18 years of age and ≤80 years of age

          2. Confirmed diagnosis of idiopathic bronchiectasis or postinfectious bronchiectasis

          3. Confirmation of infection with P. aeruginosa at screening

          4. Are sensitive to Tobramycin

          5. Acute exacerbation of bronchiectasis -

        Exclusion Criteria:

          1. Bronchiectasis due to special causes.

          2. Smokers.

          3. Are associated with bronchial asthma.

          4. Have any serious or active medical or psychiatric illness.

          5. Are not tolerant to nebulised tobramycin

          6. FEV1.0 reduces ≥ 15% after inhaling tobramycin. -
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Qi</last_name>
    <email>xiaokangqlh@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 4, 2012</lastchanged_date>
  <firstreceived_date>August 26, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong University</investigator_affiliation>
    <investigator_full_name>Qi Qian</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Bronchiectasis</keyword>
  <keyword>Tobramycin</keyword>
  <keyword>nebulised</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bronchiectasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tobramycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
